Published in Diabetes on July 17, 2013
Actos Now for Prevention of Diabetes (ACT NOW) | NCT00220961
β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care (2014) 1.42
Evidence of β-Cell Dedifferentiation in Human Type 2 Diabetes. J Clin Endocrinol Metab (2015) 1.07
Metabolic inflexibility impairs insulin secretion and results in MODY-like diabetes in triple FoxO-deficient mice. Cell Metab (2014) 0.96
β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. J Clin Endocrinol Metab (2014) 0.90
Therapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass. Diabetes Metab J (2014) 0.89
Cardiovascular impact of drugs used in the treatment of diabetes. Ther Adv Chronic Dis (2014) 0.82
The metabolic vascular syndrome - guide to an individualized treatment. Rev Endocr Metab Disord (2016) 0.76
Machine learning to predict rapid progression of carotid atherosclerosis in patients with impaired glucose tolerance. EURASIP J Bioinform Syst Biol (2016) 0.75
How does pioglitazone prevent progression of impaired glucose tolerance to diabetes? Diabetes (2013) 0.75
Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes. Diabetes Care (2016) 0.75
Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance. Age (Dordr) (2016) 0.75
Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes. BMJ Open Diabetes Res Care (2016) 0.75
When β-cells fail: lessons from dedifferentiation. Diabetes Obes Metab (2016) 0.75
Impact of the use of anti-diabetic drugs on survival of diabetic dialysis patients: a 5-year retrospective cohort study in Taiwan. Clin Exp Nephrol (2016) 0.75
Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA (2012) 33.54
Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care (1999) 26.39
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care (2006) 12.14
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med (2006) 10.97
Thiazolidinediones. N Engl J Med (2004) 9.42
Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes (1988) 7.80
The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest (1999) 7.35
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes (1998) 6.53
Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes (2002) 6.05
Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes (2005) 4.81
Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care (2006) 4.72
Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes (1992) 4.47
Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med (2011) 4.28
Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes (2006) 3.67
Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract (2007) 3.60
Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia (2010) 3.17
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab (2002) 2.98
beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab (2004) 2.91
Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia (2003) 2.80
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes (2005) 2.80
Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab (2004) 2.59
Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes (2006) 2.40
Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes (1999) 1.98
Diabetes and apoptosis: lipotoxicity. Apoptosis (2009) 1.75
Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia (2000) 1.73
Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab (2004) 1.67
Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response. Diabetes (2000) 1.63
Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest (2000) 1.58
Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab (2006) 1.41
Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia (2003) 1.22
Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord (2009) 1.15
PROactive: time for a critical appraisal. Eur Heart J (2008) 1.11
Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function. J Clin Endocrinol Metab (2004) 1.10
Adipocytes in subjects with impaired fasting glucose and impaired glucose tolerance are resistant to the anti-lipolytic effect of insulin. Acta Diabetol (2008) 1.07
Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab (2010) 1.01
Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. Diabetes (2005) 0.97
Obese premenopausal African-American women with normal and impaired glucose tolerance have a similar degree of insulin resistance but differ in beta-cell function. Diabetes Care (2001) 0.78
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science (2007) 43.16
Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med (2008) 25.70
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care (2010) 18.00
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med (2009) 12.38
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med (2006) 10.97
Variants in MTNR1B influence fasting glucose levels. Nat Genet (2008) 10.85
Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med (2006) 9.53
Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab (2002) 8.90
Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis. Diabetes Care (2010) 8.52
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
A better index of body adiposity. Obesity (Silver Spring) (2011) 7.53
Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care (2006) 7.09
Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation (2010) 6.86
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care (2004) 6.64
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med (2005) 6.63
Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care (2007) 6.38
Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care (2007) 6.24
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care (2005) 5.77
Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obes Res (2004) 5.74
Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem (2003) 5.40
Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA (2012) 5.15
Fast-food consumption among US adults and children: dietary and nutrient intake profile. J Am Diet Assoc (2003) 5.13
Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care (2006) 4.72
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract (2011) 4.69
Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med (2011) 4.28
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (2010) 4.23
Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care (2003) 4.22
SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov (2010) 4.22
Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care (2004) 4.17
Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med (2012) 3.95
Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med (2005) 3.92
A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle. Diabetes (2005) 3.84
Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care (2006) 3.72
Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes (2006) 3.67
Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med (2015) 3.67
Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J Clin Invest (2008) 3.51
Racial differences in abdominal depot-specific adiposity in white and African American adults. Am J Clin Nutr (2009) 3.39
The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care (2014) 3.31
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest (2014) 3.31
Adiponectin: more than just another fat cell hormone? Diabetes Care (2003) 3.30
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA (2008) 3.16
Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol (2006) 3.11
Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care (2009) 3.03
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY. Endocr Pract (2016) 3.01
beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab (2004) 2.91
Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care (2006) 2.90
Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med (2012) 2.90
Sex, race/ethnicity, socioeconomic status, and BMI in relation to self-perception of overweight. Obes Res (2002) 2.87
Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes (2005) 2.76
Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes (2008) 2.76
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70
A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes (2003) 2.63
Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care (2011) 2.60
Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care (2005) 2.52
Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology (2012) 2.49
The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences. Obesity (Silver Spring) (2010) 2.47
A large set of Finnish affected sibling pair families with type 2 diabetes suggests susceptibility loci on chromosomes 6, 11, and 14. Diabetes (2004) 2.46
Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans. Diabetes (2010) 2.44
Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med (2006) 2.42
Nutrient modification of the innate immune response: a novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation. Arterioscler Thromb Vasc Biol (2010) 2.42
Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes (2006) 2.40
Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med (2008) 2.39
Hyperglycemic crises in diabetes. Diabetes Care (2004) 2.38
Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care (2003) 2.36
Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab (2004) 2.36
Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension (2004) 2.33
Erectile dysfunction in type 2 diabetic men: relationship to exercise fitness and cardiovascular risk factors in the Look AHEAD trial. J Sex Med (2009) 2.30
The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab (2008) 2.27
Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 diabetes: a time-course and dose-response study. Diabetes (2007) 2.26
Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity (Silver Spring) (2008) 2.23
The DASH diet for high blood pressure: from clinical trial to dinner table. Cleve Clin J Med (2004) 2.23
Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults. Diabetes Care (2007) 2.20
Gastric bypass and banding equally improve insulin sensitivity and β cell function. J Clin Invest (2012) 2.19
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care (2013) 2.17
Nonsurgical weight loss for extreme obesity in primary care settings: results of the Louisiana Obese Subjects Study. Arch Intern Med (2010) 2.17